Keyphrases
Rituximab
100%
Living Donor Kidney Transplantation
100%
Induction Therapy
100%
Randomized Trial
100%
Interim Analysis
66%
Trial Outcomes
66%
Randomized Controlled Trial
66%
Stopping Rule
33%
Maintenance Immunosuppression
33%
Chemotherapy Drugs
33%
Early Stopping
33%
Clinical Analysis
33%
Trial Design
33%
Trial Phase
33%
Early Termination
33%
Graft Survival
33%
Steroid Therapy
33%
Non-inferiority
33%
Early Monitoring
33%
High Probability
33%
Biopsy-proven Rejection
33%
Open-label Trial
33%
Patient Survival
33%
Acutely Ill Patients
33%
Group Sequential Design
33%
Clinical Trials
33%
Expected Sample Size
33%
NHS Trusts
33%
Patient's Will
33%
Medicine and Dentistry
Rituximab
100%
Living Donors
100%
Kidney Transplantation
100%
Interim Analysis
66%
Randomized Controlled Trial
66%
Steroid Therapy
33%
Biopsy Technique
33%
Immunosuppressive Treatment
33%
Open-Label Trial
33%
Chemotherapy
33%
Acute Graft Rejection
33%
Clinical Trial
33%